Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 5Phase 1/2 4Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 6Squamous Cell Carcinoma of Head and Neck 4Head and Neck Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Sarcoma 3Neoplasms 3Endometrial Neoplasms 3Neoplasm Metastasis 2Lymphoma 2Leukemia, Myeloid, Acute 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Smoldering Multiple Myeloma 1Skin Neoplasms 1SCLC 1Recurrence 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Muscle Invasive Bladder Urothelial Carcinoma 1Motor Activity 1Lymphoma, B-Cell 1Lung Neoplasms 1Hodgkin Disease 1Glioma 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1

Interventions

pembrolizumab 1Propranolol 1Microscopy, Electron 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1CYT-6091 1Auranofin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Carcinoma, Ovarian Epithelial × pembrolizumab × Clear all
NCT02728830 2024-02-21

A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers

Duke University

Phase EARLY_PHASE1 Completed
39 enrolled 16 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡